Scientists reveal new targets for 'most difficult' breast cancer

Fudan University Affiliated Cancer Hospital Breast Surgery Director Zhai Zhimin team in the "most difficult to treat" breast cancer called the field of three-negative breast cancer research, the first time in the world based on multi-dimensional histology big data, systematic analysis of the metabolic characteristics of triple-negative breast cancer, revealed a new target of triple-negative breast cancer, the first time based on metabolic characteristics of the treatment strategy, for three-negative breast cancer patients to obtain accurate and effective treatment as soon as possible to bring hope. On November 12, the results of the study were published in Cell-Metabolism.
three-negative breast cancer as a subtype of breast cancer, accounting for about 15% of the total breast cancer population, its estrogen, progesterone, and human skin growth factor 2 are negative expression. Due to the high degree of malignancy, easy to appear visceral metastasis, the risk of recurrence is large, the prognosm is poor, and the lack of effective special treatment strategies, known as "the most difficult to treat" breast cancer.
2019, Zhai Zhimin's team mapped the world's largest three-negative breast cancer queue. According to the different genetic characteristics of three-negative breast cancer, the international first proposed "Fudan type" standard, the three-negative breast cancer divided into four different subtypes: immunomodulation type, cavity androgen-like body type, substrate-like immunosuppressive type, interstitial type. Combined with further genetic testing, it provides an accurate solution for the effective treatment of triple negative breast cancer.
On the basis of this study, Zhai Zhimin's team conducted an "umbrella" clinical study called "FUTURE", which selected suitable treatment options "targetedly" for patients through the precise classification of "Fudan classification".
Based on the fact that triple-negative breast cancer is a hybrid type of breast cancer subtype, Zhai Zhimin's team further considered whether it would be possible to conduct research from the perspective of tumor metabolism, or would be conducive to the discovery of more specific targets for triple-negative breast cancer patients, thus optimizing the precise treatment strategy for triple-negative breast cancer.
based on the multi-group map of triple-negative breast cancer drawn earlier, the researchers cut in from the perspective of metabolic path, and through the compared analysis of a large amount of data, they found that the metabolic characteristics of triple-negative breast cancer did differ greatly in different samples.
results of the calculation of various bio-information algorithms suggest that there are three subtypes with different metabolic path characteristics in patients with triple negative breast cancer. Zhai Zhimin told the China Science Daily that the results show that different subtypes of triple-negative breast cancer are sensitive to different types of treatment options.
For example, lipid-synthetic tri-negative breast cancer is relatively sensitive to fatty acid synthase inhibitors compared to other subtypes, while glycolyzyme-modified triple-negative breast cancer is relatively sensitive to glycolysis pathliness inhibitors, and the researchers also found that this type of trisexual breast cancer can be somewhat sensitive to immunotherapy after inhibiting lactic acid dehydrogenase activity in saccharined tri-negative breast cancer. (Source: Jiang Yizhou, China Science Journal, Wang Guangzhao Huangxin)
relevant paper information: